Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09 2024 - 7:00AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, revealed results from a multi-year,
real-world study of nearly 21,000 patients that indicated those
with major depressive disorder had reduced healthcare utilization
after taking the GeneSight® Psychotropic test.
“We are encouraged by the initial results of this study that
showed how the proportion of patients with hospitalizations was
significantly reduced after GeneSight testing,” said Dale Muzzey,
chief scientific officer, Myriad Genetics. “This is the first step
in a multi-phase analysis of real-world data to further demonstrate
how the GeneSight test may improve clinical outcomes and reduce
overall healthcare costs. We expect to share additional study
results later this year.”
The study demonstrated that the percentage of patients with
hospitalizations was significantly reduced 180 days after GeneSight
testing:
- 39% relative reduction in psychiatric-related
hospitalizations.
- 29% relative reduction in hospitalizations for any reason.
- Significant reduction in hospitalizations for patients who were
switched to a medication with no or moderate gene-drug
interactions.
The study found that, among patients who took the GeneSight
test, there was a decrease in the proportion of patients who were
prescribed medications with significant gene-drug interactions
after taking the test:
- The percentage of patients who were prescribed medications in
the significant gene-drug interaction category was reduced from
26.1% to 15.9%.
- The percentage of patients who were prescribed medications with
no gene-drug interactions increased from 27.5% to 47%.
“These data suggest that healthcare providers are using the
GeneSight test to make medication decisions in the real-world,”
said Holly Johnson, Ph.D, director of medical affairs at Myriad
Genetics. “These results are consistent with multiple, prospective
studies demonstrating the utility of pharmacogenomic-guided
treatment for improving response and remission rates in major
depressive disorder.”
About the PosterTitle: “Impact
of Combinatorial Pharmacogenomic Testing on Hospitalization Rates
in a Real-World Dataset of Patients with Major Depressive
Disorder”Authors: Andria L. Del Tredici, PhD;
Priya Maheshwari, MS, RPh; Alexander Gutin, PhD; Devika Chawla,
PhD; Katie Johansen Taber, PhD; Holly L. Johnson, PhD; Andrew A.
Nierenberg, MDPresenter: Priya Maheshwari, MS,
RPh, senior medical information liaison at Myriad
GeneticsConference: American Association of
Psychiatric Pharmacists (AAPP) conference in Orlando, FL; presented
on Monday, April 8, 2024
About the StudyThe study analyzed a data set
generated by linking more than a half million de-identified
patients who received the GeneSight test to administrative
insurance claims from a nationwide data warehouse in the United
States. Nearly 21,000 depressed patients met inclusion criteria to
be in the study. The study authors then evaluated this data set
with regard to medications prescribed before and after GeneSight
testing, as well as hospitalization rates before and after
GeneSight testing. Future analysis of the data will include
investigating the impact of post-PGx medication selection on total
cost of care for depression.
About the GeneSight®
TestThe GeneSight Psychotropic test from Myriad
Genetics is the category-leading pharmacogenomic test for more than
60 medications commonly prescribed for depression, anxiety, ADHD,
and other psychiatric conditions. The GeneSight test can help
inform clinicians about how a patient’s genes may impact how they
metabolize and/or respond to certain psychiatric medications. Tens
of thousands of clinicians have ordered the GeneSight test for more
than two million patients in order to receive genetic information
that is unique to each patient. The GeneSight test supplements
other information considered by a clinician as part of a
comprehensive medical assessment. Learn more at GeneSight.com.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
that the company expects to share additional study results later
this year and future analysis of the data will include
investigating the impact of post-PGx medication selection on total
cost of care for depression. These “forward-looking statements” are
management’s expectations of future events as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on February 28, 2024, as well as
any updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Investor Contact Matt Scalo (801)
584-3532 IR@myriad.com
Media Contact Glenn Farrell (385)
318-3718 PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2024 to Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Jun 2023 to Jun 2024